Ritonavir microemulsion formulation for treating viral infections such as coronavirus disease-19, comprises ritonavir, an oil phase, surfactant, co-surfactant, aqueous phase
	MANSI F; PATEL P
	2023-09-26
专利权人	MANSI F (MANS-Individual) ; PATEL P (PATE-Individual) ; UNIV SAURASHTRA (UYSA-Non-standard)
申请日期	2023-09-26
专利号	IN202321064574-A
成果简介	NOVELTY - Ritonavir microemulsion formulation comprises ritonavir, an oil phase, surfactant, co-surfactant, aqueous phase. USE - Ritonavir microemulsion formulation for treating viral infections such as coronavirus disease (COVID)-19. ADVANTAGE - The ritonavir microemulsion formulation exhibits 95.32% drug release at 12 hours, exhibits improved solubility and bioavailability, is stable, safe and effective, leads to lowering of dose and increase in safety and efficacy, and exhibits bio equivalency against marketed tablet formulations. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing ritonavir microemulsion formulation, comprising: (a) mixing oil phase, surfactant and co-surfactant on a magnetic stirrer; (b) dissolving ritonavir mixture; (c) adding distilled water dropwise in mixture to obtain transparent microemulsion; (d) homogenizing microemulsion at 500 rpm for 10 minutes to achieve desired globule size of the microemulsion.
IPC 分类号	A61K-031/166 ; A61K-031/427 ; A61K-031/7036 ; A61P-031/12 ; A61P-031/14
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20237
专题	中国科学院新疆生态与地理研究所
作者单位	1.MANSI F (MANS-Individual) 2.PATEL P (PATE-Individual) 3.UNIV SAURASHTRA (UYSA-Non-standard)
推荐引用方式 GB/T 7714	MANSI F,PATEL P. Ritonavir microemulsion formulation for treating viral infections such as coronavirus disease-19, comprises ritonavir, an oil phase, surfactant, co-surfactant, aqueous phase. IN202321064574-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。